Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28320699 | 0.85 | LMNA (0.42) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL31663089 | 0.79 | LMNA (0.35) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL31663012 | 0.79 | LMNA (0.35) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL2423501 | 0.73 | TSHR (0.46) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL28142794 | 0.72 | CD44 (0.45) | LMNASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL20489081 | 0.72 | G6PD (0.38) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL28459050 | 0.72 | REV1 (0.34) | — | |
| SCHEMBL31473075 | 0.69 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL4456223 | 0.69 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL28142021 | 0.69 | SIGMAR1 (0.38) | ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246108-A1 | Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative | TOKUYAMA CORPORATION (JP) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246108-A1 | Method for Producing Alpha-Azidoaniline Derivative or Alpha,AlphaPrime-Diazide Derivative | QDPR, AZI2, NISCH | LMNA 2812/4885SMN1; SMN2 3244/4885MEN1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.